VZIO - Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session | Benzinga
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
Fluor posted adjusted earnings of 68 cents per share, beating market estimates of 57 cents per share. The company’s quarterly sales came in at $3.82 billion versus expectations of $4.11 billion.
Fluor shares declined 7.7% to $38.84 on Tuesday.
Here are some other stocks moving in today's mid-day session.
Gainers
- TRxADE HEALTH, Inc. (NASDAQ: MEDS) shares jumped 214% to $13.00. TRxADE HEALTH announced the sale of assets of subsidiary Trxade, Inc. to Micro Merchant Systems for $22.5 million, with potential additional $7.5 million payout.
- AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) surged 203% to $0.6487. AgriFORCE was granted patent from the USPTO related to its FORCEGH+ facilities.
- Monopar Therapeutics Inc. (NASDAQ: MNPR) shares jumped 170% to $0.9130. Monopar received clearance to proceed with first-in-human Phase 1 trial of novel radiopharmaceutical MNPR-101-Zr in advanced cancers.
- Biofrontera Inc. (NASDAQ: BFRI) gained 125% to $1.69. Biofrontera announced restructuring of supply agreement with Biofronter AG. Biofrontera also announced a $16 million private placement.
- Biotricity, Inc. (NASDAQ: BTCY) rose 72.7% to $1.59.
- Shineco, Inc. (NASDAQ: SISI) shares climbed 71.8% to $2.5232 after surging more than 16% on Friday. Shineco recently announced plans for a 1-for-10 reverse stock split to regain compliance with Nasdaq minimum bid requirement.
- SciSparc Ltd. (NASDAQ: SPRC) gained 52.7% to $5.32. SciSparc reported that as part of its ongoing collaboration with Clearmind Medicine, Clearmind filed three patent applications under the international Patent Cooperation Treaty.
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares rose 37% to $12.55. WuXi Advanced Therapies announced Tuesday that the U.S. Food and Drug Administration (FDA) approved it to begin analytical testing and manufacturing of AMTAGVI for Iovance Biotherapeutics at its Philadelphia site. AMTAGVI received accelerated approval of its BLA on Feb. 16. Iovance also ...